慢性心力衰竭患者肺动脉压远程血流动力学监测(MONITOR-HF):一项随机临床试验
MONITOR-HF 是在荷兰25个中心开展的非盲随机试验,纳入348例纽约心脏协会III级且有既往心衰住院史的慢性心衰患者,1:1随机分至肺动脉压血流动力学监测(CardioMEMS-HF系统)组或标准治疗组。12个月时KCCQ总体汇总评分平均变化组间差为7.13(95%CI 1.51-12.75;p=0.013),监测组改善7.05(p=0.0014),标准治疗组变化-0.08(p=0.97)。
要点
- 12个月KCCQ总体汇总评分平均变化组间差7.13(95%CI 1.51-12.75;p=0.013),监测组+7.05,标准治疗组-0.08。
- KCCQ总体汇总评分改善至少5分的OR为1.69(95%CI 1.01-2.83;p=0.046),恶化至少5分的OR为0.45(95%CI 0.26-0.77;p=0.0035)。
- 无器械相关或系统相关并发症及传感器故障的比例分别为97.7%和98.8%。
核心结论
- 在按当代指南治疗的中重度心衰患者中,肺动脉压血流动力学监测大幅改善生活质量并减少心衰住院。
研究设计与样本
- MONITOR-HF为在荷兰25个中心开展的非盲随机试验,纳入纽约心脏协会III级且有既往心衰住院史的慢性心衰患者,不限射血分数。
- 2019年4月1日至2022年1月14日随机分配348例患者至CardioMEMS-HF组(n=176,51%)或对照组(n=172,49%)。
- 中位年龄69岁(IQR 61-75),中位射血分数30%(23-40)。
- 主要终点为12个月时堪萨斯城心肌病问卷(KCCQ)总体汇总评分的平均差异,全部分析按意向性治疗进行。
主要发现
- 12个月KCCQ总体汇总评分平均变化组间差为7.13(95%CI 1.51-12.75;p=0.013),CardioMEMS组变化+7.05(p=0.0014),标准治疗组变化-0.08(p=0.97)。
- 应答分析中,CardioMEMS-HF组较标准治疗组KCCQ总体汇总评分改善至少5分的OR为1.69(95%CI 1.01-2.83;p=0.046),恶化至少5分的OR为0.45(95%CI 0.26-0.77;p=0.0035)。
- 无器械相关或系统相关并发症及传感器故障的比例分别为97.7%和98.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of haemodynamic monitoring of pulmonary artery pressure has predominantly been studied in the USA. There is a clear need for randomised trial data from patients treated with contemporary guideline-directed-medical-therapy with long-term follow-up in a different health-care system. METHODS: MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of ejection fraction. Patients were randomly assigned (1:1) to haemodynamic monitoring (CardioMEMS-HF system, Abbott Laboratories, Abbott Park, IL, USA) or standard care. All patients were scheduled to be seen by their clinician at 3 months and 6 months, and every 6 months thereafter, up to 48 months. The primary endpoint was the mean difference in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score at 12 months. All analyses were by intention-to-treat. This trial was prospectively registered under the clinical trial registration number NTR7673 (NL7430) on the International Clinical Trials Registry Platform. FINDINGS: Between April 1, 2019, and Jan 14, 2022, we randomly assigned 348 patients to either the CardioMEMS-HF group (n=176 [51%]) or the control group (n=172 [49%]). The median age was 69 years (IQR 61-75) and median ejection fraction was 30% (23-40). The difference in mean change in KCCQ overall summary score at 12 months was 7·13 (95% CI 1·51-12·75; p=0·013) between groups (+7·05 in the CardioMEMS group, p=0·0014, and -0·08 in the standard care group, p=0·97). In the responder analysis, the odds ratio (OR) of an improvement of at least 5 points in KCCQ overall summary score was OR 1·69 (95% CI 1·01-2·83; p=0·046) and the OR of a deterioration of at least 5 points was 0·45 (0·26-0·77; p=0·0035) in the CardioMEMS-HF group compared with in the standard care group. The freedom of device-related or system-related complications and sensor failure were 97·7% and 98·8%, respectively. INTERPRETATION: Haemodynamic monitoring substantially improved quality of life and reduced heart failure hospitalisations in patients with moderate-to-severe heart failure treated according to contemporary guidelines. These findings contribute to the aggregate evidence for this technology and might have implications for guideline recommendations and implementation of remote pulmonary artery pressure monitoring. FUNDING: The Dutch Ministry of Health, Health Care Institute (Zorginstituut), and Abbott Laboratories.
引用
- Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023. PMID: 37220768. doi:10.1016/S0140-6736(23)00923-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。